肿瘤预防与治疗2026，Vol.39Issue(8)：700-707,8.DOI:10.3969/j.issn.1674-0904.2026.08.010
皮肤鳞状细胞癌生物治疗的研究进展
Research Progress on Biotherapy for Cutaneous Squamous Cell Carcinoma
摘要
Abstract
Cutaneous squamous cell carcinoma(cSCC)is a common malignant tumor of the skin.Early-stage patients can achieve good prognosis through treatment methods such as surgery and radiation therapy,but there are still some who pro-gress to the advanced stage with poor prognosis.In recent years,with a deeper understanding of the molecular mechanisms of cSCC—including gene mutations(e.g.,TP53 and Notch),pathway aberrations(e.g.,EGFR signaling),high tumor mu-tational burden,and an immunosuppressive microenvironment—the treatment of cSCC has entered the era of biologic thera-py.Targeted therapy represented by EGFR inhibitors(such as cetuximab)and immunotherapy centered around programmed death-1 inhibitors(such as cemiplimab)have become important choices for advanced patients,with immunotherapy becom-ing a first-line option.Combination therapy strategies,such as targeted therapy plus immunotherapy,have also shown the po-tential to enhance efficacy and overcome drug resistance.This article will systematically review the clinical application pro-gress of drugs related to targeted therapy,immunotherapy,and their combination in cSCC.关键词
皮肤鳞状细胞癌/靶向治疗/免疫治疗/EGFR/免疫检查点抑制剂/进展Key words
Cutaneous squamous cell carcinoma/Targeted therapy/Immunotherapy/EGFR/Immune checkpoint inhibi-tors/Progress分类
医药卫生引用本文复制引用
范昔庚,张斌斌,胥锡耀,陈俊杰..皮肤鳞状细胞癌生物治疗的研究进展[J].肿瘤预防与治疗,2026,39(8):700-707,8.基金项目
This study was supported by grants from Health Commission of Zigong(No.23yb010). 自贡市卫生健康系统科研课题(编号:23yb010) （No.23yb010）
